Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial
- Resource Type
- Article
- Source
- In
eClinicalMedicine April 2024 70 - Subject
Primary Research Articles - Language
- ISSN
- 2589-5370